Key result
Luteolin cotreatment reduced doxorubicin-induced oxidative stress, inflammation, apoptosis, and pathological lesions in the brains of Wistar rats.
Why the study?
Doxorubicin is used to treat various cancer types, but its toxic side effects include neuronopathy and memory deficits.
Does luteolin reduce doxorubicin-induced neurotoxicity in Wistar rats?
Does luteolin reduce doxorubicin-induced neurotoxicity in Wistar rats?
Luteolin mitigates doxorubicin-induced neurotoxicity in rats by reducing oxidative stress, inflammation, and apoptosis.
Hypothesis-generating in rat models; leaves open clinical translation for doxorubicin neurotoxicity.
Doxorubicin (DOX) is a chemotherapeutic drug used in the treatment of various cancer types. DOX toxic side effects include neuronopathy and memory deficits. We investigated the effect of the antioxidant luteolin (LUT: 50 or 100 mg/kg; per os) on DOX (2 mg/kg; intraperitoneal)-induced oxidative stress (OS), inflammation, and apoptosis in the brain of Wistar rats for 14 days. We observed that LUT reduced DOX-mediated increase in OS biomarkers-catalase, superoxide dismutase, glutathione-S-transferase, and glutathione peroxidase. LUT increased glutathione and total sulphydryl levels and alleviated DOX-induced increases in the levels of reactive oxygen and nitrogen species, lipid peroxidation, myeloperoxidase, nitric oxide, tumor necrosis factor-α, and interleukin-1β (IL-1β). Additionally, LUT suppressed caspase-3 activity, increased anti-inflammatory cytokine-IL-10 level, and reduced pathological lesions in the examined organs of rats cotreated with LUT and DOX. Collectively, cotreatment with LUT lessened DOX-induced neurotoxicity. Supplementation of LUT as a chemopreventive agent might be useful in patients undergoing DOX chemotherapy.
No takes yet. Share an insight, caveat, or question.
Imosemi et al. (2021) studied Doxorubicin-induced neurotoxicity. Luteolin vs. Doxorubicin alone was evaluated on Oxidative stress, inflammation, and apoptosis in the brain. Luteolin cotreatment reduced doxorubicin-induced oxidative stress, inflammation, apoptosis, and pathological lesions in the brains of Wistar rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: